MedTrace Logo

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

NCT05154344 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2023-01-06

No results posted yet for this study

Summary

CapmATU study will evaluate time to treatment failure, progression-free survival, overall survival, best response and safety in patients with advanced MET-dysregulated non-small cell lung cancer who received capmatinib as part of an expanded access program. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.

Conditions

  • MET Alterations
  • Non Small Cell Lung Cancer
  • METex14 Mutations

Interventions

DRUG

Capmatinib

Available through expanded access

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2022-02-01
Completion
2022-02-01

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05154344 on ClinicalTrials.gov